Siltuximab, an anti-IL6 monoclonal antibody drug used in clinic, was shown to be effective in reducing hepcidin expression in patients with Castleman’s disease (CD) and in improving their anemia (van Rhee et al., 2010). The gene discussed is IL6; the disease is anemia (phenotype).